Aarhus University Seal / Aarhus Universitets segl

Lars Poulsen Tolbod

Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer : Analytic and Clinical Validation. / Jochumsen, Mads R.; Tolbod, Lars P.; Pedersen, Bodil G.; Nielsen, Maria M.; Hoyer, Soren; Frokiaer, Jorgen; Borre, Michael; Bouchelouche, Kirsten; Sorensen, Jens.

In: Journal of Nuclear Medicine, Vol. 60, No. 8, 08.2019, p. 1059-1065.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{55aeb7c17ec843328522306e60eda390,
title = "Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation",
abstract = "The aim of this work was to evaluate Rb-82 PET/CT as a diagnostic tool for quantitative tumor blood flow (TBF) imaging in prostate cancer (PCa). Study 1 was performed to evaluate Rb-82 as a marker of TBF, using O-15-H2O PET as a reference method. Study 2 investigated the ability of Rb-82 uptake measurements to differentiate between PCa and normal prostate. Methods: Study 1:9 PCa patients scheduled for radical prostatectomy were included. Prostate multiparametric MRI and both cardiac and pelvic O-15-H2O PET and Rb-82 PET were performed. PET findings were compared with postprostatectomy Gleason grade group (GGG). Study 2:15 primary high-risk PCa patients and 12 controls without known prostate disease were included in a clinical drug trial (EudraCT 2016-003185-26). Ga-68-prostate-specific membrane antigen PET/CT scans of PCa patients were available. Pelvic Rb-82 PET was performed. Results: Study 1: both Rb-82 K-1 and Rb-82 SUVs correlated strongly with O-15-H2O TBF (rho = 0.95, P <0.001, and rho = 0.77, P = 0.015, respectively). Rb-82 SUV and K-1 were linearly correlated (r = 0.92, P = 0.001). Rb-82 SUV correlated with postprostatectomy GGG (rho = 0.70, P = 0.03). Study 2: Rb-82 SUV in PCa (3.19 +/- 0.48) was significantly higher than prostate Rb-82 SUV in healthy controls (1.68 +/- 0.37) (P <0.001), with no overlap between groups. Conclusion: Study 1 shows that Rb-82 Rb-82 PET/CT can be used for TBF quantification and that TBF can be estimated by simple SUV and suggests that Rb-82 SUV is associated with postprostatectomy GGG and, hence, cancer aggressiveness. Study 2 shows that Rb-82 uptake is significantly higher in PCa than in normal prostate tissue with no overlap between cohorts, confirming the primary hypothesis of the clinical trial. Consequently, Rb-82 PET/CT may have potential as a noninvasive tool for evaluation of tumor aggressiveness and monitoring in nonmetastatic PCa.",
keywords = "Rb-82 PET, O-15-H2O PET, prostate cancer, tumor perfusion, cancer, BLOOD-FLOW, RADICAL PROSTATECTOMY, TL-201 SPECT, QUANTIFICATION, HALLMARKS, BIOPSIES",
author = "Jochumsen, {Mads R.} and Tolbod, {Lars P.} and Pedersen, {Bodil G.} and Nielsen, {Maria M.} and Soren Hoyer and Jorgen Frokiaer and Michael Borre and Kirsten Bouchelouche and Jens Sorensen",
year = "2019",
month = aug,
doi = "10.2967/jnumed.118.219188",
language = "English",
volume = "60",
pages = "1059--1065",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "SOC NUCLEAR MEDICINE INC",
number = "8",

}

RIS

TY - JOUR

T1 - Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer

T2 - Analytic and Clinical Validation

AU - Jochumsen, Mads R.

AU - Tolbod, Lars P.

AU - Pedersen, Bodil G.

AU - Nielsen, Maria M.

AU - Hoyer, Soren

AU - Frokiaer, Jorgen

AU - Borre, Michael

AU - Bouchelouche, Kirsten

AU - Sorensen, Jens

PY - 2019/8

Y1 - 2019/8

N2 - The aim of this work was to evaluate Rb-82 PET/CT as a diagnostic tool for quantitative tumor blood flow (TBF) imaging in prostate cancer (PCa). Study 1 was performed to evaluate Rb-82 as a marker of TBF, using O-15-H2O PET as a reference method. Study 2 investigated the ability of Rb-82 uptake measurements to differentiate between PCa and normal prostate. Methods: Study 1:9 PCa patients scheduled for radical prostatectomy were included. Prostate multiparametric MRI and both cardiac and pelvic O-15-H2O PET and Rb-82 PET were performed. PET findings were compared with postprostatectomy Gleason grade group (GGG). Study 2:15 primary high-risk PCa patients and 12 controls without known prostate disease were included in a clinical drug trial (EudraCT 2016-003185-26). Ga-68-prostate-specific membrane antigen PET/CT scans of PCa patients were available. Pelvic Rb-82 PET was performed. Results: Study 1: both Rb-82 K-1 and Rb-82 SUVs correlated strongly with O-15-H2O TBF (rho = 0.95, P <0.001, and rho = 0.77, P = 0.015, respectively). Rb-82 SUV and K-1 were linearly correlated (r = 0.92, P = 0.001). Rb-82 SUV correlated with postprostatectomy GGG (rho = 0.70, P = 0.03). Study 2: Rb-82 SUV in PCa (3.19 +/- 0.48) was significantly higher than prostate Rb-82 SUV in healthy controls (1.68 +/- 0.37) (P <0.001), with no overlap between groups. Conclusion: Study 1 shows that Rb-82 Rb-82 PET/CT can be used for TBF quantification and that TBF can be estimated by simple SUV and suggests that Rb-82 SUV is associated with postprostatectomy GGG and, hence, cancer aggressiveness. Study 2 shows that Rb-82 uptake is significantly higher in PCa than in normal prostate tissue with no overlap between cohorts, confirming the primary hypothesis of the clinical trial. Consequently, Rb-82 PET/CT may have potential as a noninvasive tool for evaluation of tumor aggressiveness and monitoring in nonmetastatic PCa.

AB - The aim of this work was to evaluate Rb-82 PET/CT as a diagnostic tool for quantitative tumor blood flow (TBF) imaging in prostate cancer (PCa). Study 1 was performed to evaluate Rb-82 as a marker of TBF, using O-15-H2O PET as a reference method. Study 2 investigated the ability of Rb-82 uptake measurements to differentiate between PCa and normal prostate. Methods: Study 1:9 PCa patients scheduled for radical prostatectomy were included. Prostate multiparametric MRI and both cardiac and pelvic O-15-H2O PET and Rb-82 PET were performed. PET findings were compared with postprostatectomy Gleason grade group (GGG). Study 2:15 primary high-risk PCa patients and 12 controls without known prostate disease were included in a clinical drug trial (EudraCT 2016-003185-26). Ga-68-prostate-specific membrane antigen PET/CT scans of PCa patients were available. Pelvic Rb-82 PET was performed. Results: Study 1: both Rb-82 K-1 and Rb-82 SUVs correlated strongly with O-15-H2O TBF (rho = 0.95, P <0.001, and rho = 0.77, P = 0.015, respectively). Rb-82 SUV and K-1 were linearly correlated (r = 0.92, P = 0.001). Rb-82 SUV correlated with postprostatectomy GGG (rho = 0.70, P = 0.03). Study 2: Rb-82 SUV in PCa (3.19 +/- 0.48) was significantly higher than prostate Rb-82 SUV in healthy controls (1.68 +/- 0.37) (P <0.001), with no overlap between groups. Conclusion: Study 1 shows that Rb-82 Rb-82 PET/CT can be used for TBF quantification and that TBF can be estimated by simple SUV and suggests that Rb-82 SUV is associated with postprostatectomy GGG and, hence, cancer aggressiveness. Study 2 shows that Rb-82 uptake is significantly higher in PCa than in normal prostate tissue with no overlap between cohorts, confirming the primary hypothesis of the clinical trial. Consequently, Rb-82 PET/CT may have potential as a noninvasive tool for evaluation of tumor aggressiveness and monitoring in nonmetastatic PCa.

KW - Rb-82 PET

KW - O-15-H2O PET

KW - prostate cancer

KW - tumor perfusion

KW - cancer

KW - BLOOD-FLOW

KW - RADICAL PROSTATECTOMY

KW - TL-201 SPECT

KW - QUANTIFICATION

KW - HALLMARKS

KW - BIOPSIES

U2 - 10.2967/jnumed.118.219188

DO - 10.2967/jnumed.118.219188

M3 - Journal article

C2 - 30683762

VL - 60

SP - 1059

EP - 1065

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -